Anthony Keech

45.5k total citations · 9 hit papers
298 papers, 23.8k citations indexed

About

Anthony Keech is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Anthony Keech has authored 298 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Surgery, 78 papers in Endocrinology, Diabetes and Metabolism and 77 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Anthony Keech's work include Lipoproteins and Cardiovascular Health (98 papers), Health Systems, Economic Evaluations, Quality of Life (62 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (41 papers). Anthony Keech is often cited by papers focused on Lipoproteins and Cardiovascular Health (98 papers), Health Systems, Economic Evaluations, Quality of Life (62 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (41 papers). Anthony Keech collaborates with scholars based in Australia, United States and United Kingdom. Anthony Keech's co-authors include Colin Baigent, Lisa Blackwell, Adrienne Kirby, John Simes, Jonathan Emberson, Patricia M. Kearney, C Pollicino, Christina Reith, T. Sourjina and Georgina Buck and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Anthony Keech

292 papers receiving 22.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

2005 5.0k citations Anthony Keech, Lisa Blackwell et al. profile →
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

2010 4.4k citations Lisa Blackwell, Jonathan Emberson et al. profile →
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

2019 585 citations Michelle L. O’Donoghue, Robert P. Giugliano et al. Circulation profile →
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

2017 491 citations Marc P. Bonaca, Patrice Nault et al. Circulation profile →
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

2017 469 citations Robert P. Giugliano, Terje R. Pedersen et al. profile →
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

2017 400 citations Marc S. Sabatine, Lawrence A. Leiter et al. The Lancet Diabetes & Endocrinology profile →
Cognitive Function in a Randomized Trial of Evolocumab

2017 329 citations Robert P. Giugliano, François Mach et al. New England Journal of Medicine profile →
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial

2020 213 citations Gary Wittert, Karen Bracken et al. The Lancet Diabetes & Endocrinology profile →
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

2022 211 citations Michelle L. O’Donoghue, Robert P. Giugliano et al. Circulation profile →

Peers

Countries citing papers authored by Anthony Keech

Since Specialization

Citations

This map shows the geographic impact of Anthony Keech's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Keech with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Keech more than expected).

Fields of papers citing papers by Anthony Keech

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Keech. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Keech. The network helps show where Anthony Keech may publish in the future.

Co-authorship network of co-authors of Anthony Keech

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Keech. A scholar is included among the top collaborators of Anthony Keech based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Keech. Anthony Keech is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke 2025 ·Circulation ·(unknown), Peter J. Kelly, Michelle L. O’Donoghue, Jeong‐Gun Park, Erin A. Bohula, Jeffrey L. Saver, Dan Atar, Anthony Keech, Peter S. Sever, Huei Wang, Gabriel Paiva da Silva Lima, Marc S. Sabatine, Robert P. Giugliano	1
2	Optimised plasma sample preparation and LC‐MS analysis to support large‐scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial 2023 ·PROTEOMICS - CLINICAL APPLICATIONS ·Matthew B. O’Rourke, Andrzej S. Januszewski, David Sullivan, Imre Lengyel, Alan J. Stewart, Swati Arya, Ronald C.W., Sanjeev Galande, Anandwardhan A. Hardikar, Mugdha V. Joglekar, Anthony Keech, Alicia J. Jenkins, Mark P. Molloy	8
3	Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study 2023 ·Diabetes/Metabolism Research and Reviews ·Angela Sheu, Rachel O’Connell, Alicia J. Jenkins, Thach Tran, Paul Drury, David Sullivan, (unknown), Peter G. Colman, Richard O’Brien, Y. Antero Kesäniemi, Chris White, Anthony Keech	7
4	Impact of Missing Data on the Accuracy of Glucose Metrics from Continuous Glucose Monitoring Assessed Over a 2-Week Period 2023 ·Diabetes Technology & Therapeutics ·Grant J. Smith, Mary B. Abraham, Martin de Bock, (unknown), R. Bruce King, Geoffrey Ambler, Fergus Cameron, Sybil A. McAuley, Anthony Keech, Alicia J. Jenkins, Elizabeth A. Davis, David N. O’Neal, Timothy W. Jones	11
5	Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease breakdown → 2022 ·Circulation ·Michelle L. O’Donoghue, Robert P. Giugliano, Stephen D. Wiviott, Dan Atar, Anthony Keech, Julia Kuder, (unknown), Sabina A. Murphy, Jose H. Flores‐Arredondo, J. Antonio G. López, Mary Elliott‐Davey, Bei Wang, Maria Laura Monsalvo, Siddique Abbasi, Marc S. Sabatine	211
6	Hybrid closed‐loop therapy with a first‐generation system increases confidence and independence in diabetes management in youth with type 1 diabetes 2022 ·Diabetic Medicine ·Alison Roberts, Leanne Fried, Julie Dart, Martin de Bock, (unknown), Bruce R. King, Geoffrey Ambler, Fergus Cameron, Sybil A. McAuley, Anthony Keech, Alicia J. Jenkins, David N. O’Neal, Elizabeth A. Davis, Timothy W. Jones, Mary B. Abraham	11
7	Protocol for the Stimulating β ₃ -Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease 2021 ·BMJ Open ·Kristen J. Bubb, Jason A. Harmer, (unknown), Sarah Aitken, (unknown), Laurent Billot, Clara K Chow, Jonathan Golledge, Rebecca Mister, Michael P. Gray, Stuart M. Grieve, Naomi M. Hamburg, Anthony Keech, Sanjay Patel, Vikram Puttaswamy, Gemma A. Figtree	6
8	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism 2020 ·Circulation ·Nicholas Marston, Yared Gurmu, Giorgio Melloni, Marc P. Bonaca, Bariş Gencer, Peter S. Sever, Terje R. Pedersen, Anthony Keech, Carolina Roselli, Steven A. Lubitz, Patrick T. Ellinor, Michelle L. O’Donoghue, Robert P. Giugliano, Christian T. Ruff, Marc S. Sabatine	65
9	Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register 2020 ·Diabetes Care ·Feifei Cheng, Andrea O. Y. Luk, (unknown), Baoqi Fan, Hongjiang Wu, Aimin Yang, Eric S. H. Lau, Alex C.W. Ng, Cadmon K.P. Lim, Heung Man Lee, Elaine Chow, Alice P.S. Kong, Anthony Keech, (unknown), Wing Yee So, Alicia J. Jenkins, Juliana C.N. Chan, (unknown), Ronald C.W.	41
10	A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trial 2019 ·Clinical Trials ·Karen Bracken, Anthony Keech, Wendy Hague, Carolyn A Allan, Ann J. Conway, Mark Daniel, Val Gebski, Mathis Grossmann, David J. Handelsman, Warrick J. Inder, Alicia J. Jenkins, Robert I. McLachlan, Kristy Robledo, Bronwyn Stuckey, Bu B. Yeap, Gary Wittert	1
11	Abstract 13871: Evolocumab and Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: Analysis From FOURIER 2019 ·Circulation ·Bariş Gencer, François Mach, Sabina A. Murphy, Gaetano Maria De Ferrari, Kurt Huber, Basil S. Lewis, Jorge Ferreira, Christopher E. Kurtz, Huei Wang, Narimon Honarpour, Anthony Keech, Peter S. Sever, Terje R. Pedersen, Marc S. Sabatine, Robert P. Giugliano	1
12	Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein 2019 ·Diabetes ·Jun Yuan, Joanne T. M. Tan, Kushwin Rajamani, (unknown), (unknown), Laura Lecce, P. Simpson, Yuen Ting Lam, Alicia J. Jenkins, Christina A. Bursill, Anthony Keech, M. Ng	22
13	Recruitment strategies in randomised controlled trials of men aged 50 years and older: a systematic review 2019 ·BMJ Open ·Karen Bracken, Lisa Askie, Anthony Keech, Wendy Hague, Gary Wittert	25
14	Inflammatory and Cholesterol Risk in the FOURIER Trial 2018 ·Circulation ·Erin A. Bohula, Robert P. Giugliano, Lawrence A. Leiter, Subodh Verma, Jeong‐Gun Park, Peter Sever, Armando Lira Pineda, Narimon Honarpour, Huei Wang, Sabina A. Murphy, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine	193
15	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease breakdown → 2017 ·Circulation ·Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony Keech, Armando Lira Pineda, Estella Kanevsky, Julia Kuder, Sabina A. Murphy, J. Wouter Jukema, Basil S. Lewis, Lâle Tokgözoğlu, Ransi Somaratne, Peter Sever, Terje R. Pedersen, Marc S. Sabatine	491
16	Supplement to: Evolocumab and clinical outcomes in patients with cardiovascular disease. 2017 ·New England Journal of Medicine ·Marc S. Sabatine, Robert P. Giugliano, Anthony Keech	2
17	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials 2016 ·The Lancet Diabetes & Endocrinology ·(unknown), William G. Herrington, Jonathan Emberson, Borislava Mihaylova, Lisa Blackwell, Christina Reith, Marit D. Solbu, Patrick B. Mark, Bengt Fellström, Alan G. Jardine, Christoph Wanner, Hallvard Holdaas, Jordan Fulcher, Richard Haynes, Martin Landray, Anthony Keech, John Simes, Rory Collins	203
18	Predictors of peripheral neuropathy and effects of fenofibrate among 9,795 subjects with type 2 diabetes: the fenofibrate intervention and event lowering in diabetes (FIELD) study 2011 ·Diabetologia ·Anthony Keech, Jaya Rajamani, James D. Best, Graeme J. Hankey, Mark W. Donoghoe, Linda Li, Alicia J. Jenkins, (unknown), Timothy M. E. Davis, Peta Phillips, Philip J. Barter	0
19	Abstract 18987: Fenofibrate Reduces Peripheral Neuropathy in Type 2 Diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study 2010 ·Circulation ·Kushwin Rajamani, Mark W. Donoghoe, Liping Li, (unknown), Peter G. Colman, Paul Drury, Markku Laakso, Anthony Keech	2
20	Effect of Pravastatin in People with Diabetes and Chronic Kidney Disease 2005 ·Journal of the American Society of Nephrology ·Marcello Tonelli, Anthony Keech, (unknown), Frank M. Sacks, Andrew Tonkin, Chris J. Packard, Marc A. Pfeffer, John Simes, Chris Isles, Curt D. Furberg, Malcolm West, Tim Craven, Gary C. Curhan	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact